Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› NSCLC
Clinical trial register · China

NSCLC Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 18 Beijing 16 Changsha 9 Hangzhou 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital5 Shanghai Chest Hospital4 Fudan University3 Sichuan University3 Allist Pharmaceuticals, Inc.3
Site location
Shanghai18 Guangzhou18 Beijing16 Changsha9 Hangzhou8
All 40 locations
Target enrolment
to

NSCLC trials in China

84 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Shanghai Jeyou Pharmaceutical Co., Ltd.
Phase 3
416
Nanchang
2026-10
Recruiting
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
NCT07622706NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2026-09-03
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
206
Jilin City, Shanghai
2026-08-07
Not yet open
Sichuan University
Phase 1
21
Chengdu
2026-06-30
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2026-06-30
Recruiting
Wen-zhao ZHONG
Not applicable
585
Guangzhou
2026-05-18
Not yet open
The Third Xiangya Hospital of Central South University
Phase 2
152
Changsha
2026-05-15
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
43
Hangzhou
2026-04-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-04-01
Not yet open
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
45
Guangzhou
2026-04-01
Recruiting
Shanghai Henlius Biotech
Early Phase 1
254
Shanghai, Xi'an
2025-12-29
Not yet open
Jiangsu Cancer Institute & Hospital
Phase 2
24
Nanjing
2025-12-18
Recruiting
HC Biopharma Inc.
Phase 2
50
Shanghai
2025-12-09
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
41
Tianjin
2025-12-01
Recruiting
Qian Chu
Observational
500
Wuhan, Hangzhou
2025-12-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
36
Beijing
2025-11-27
Recruiting
People's Hospital of Quzhou
Phase 2
112
Quzhou
2025-11-01
Recruiting
Guangdong Association of Clinical Trials
Not applicable
40
Guangzhou
2025-10-25
Not yet open
Fudan University
Phase 2
30
Shanghai
2025-09-30
Not yet open
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
450
Guangzhou
2025-09-22
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2025-09-20
Recruiting
Jiangsu Cancer Institute & Hospital
Phase 2
33
Nanjing
2025-09-04
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 2
28
Guangzhou, Zhuhai
2025-09
Recruiting
The Third Xiangya Hospital of Central South University
Phase 2
35
Changsha, Hengyang, Jishou
2025-08-29
Not yet open
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xi’an, Hangzhou
2025-07-31
Recruiting
Qilu Hospital of Shandong University
Phase 2
34
Jinan
2025-07-25
Recruiting
Allist Pharmaceuticals, Inc.
Phase 3
338
Beijing, Guangdong
2025-05-28
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
78
Guangzhou
2025-05-20
Recruiting
PET/CT for Trop2 ADC Response Evaluation NSCLC
NCT07151898NSCLC, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2025-05-01
Active, closed
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2
44
Shanghai
2025-04-30
Recruiting
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
NCT07092202Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor
DrugsFurmonertinib·Pemetrexed
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4
40
Wuhan
2025-04-15
Recruiting
Peking University Cancer Hospital & Institute
Not applicable
286
Beijing
2025-04-06
Recruiting
Henan Cancer Hospital
Phase 2
146
Zhengzhou
2025-04-02
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
300
Beijing
2025-03-07
Recruiting
Shanghai Chest Hospital
Phase 2
124
Shanghai
2025-02-20
Recruiting
Tang-Du Hospital
Phase 2
27
Changsha, Yinchuan, Xi'an
2025-02-18
Recruiting
Fudan University
Phase 2
27
Shanghai
2025-02-15
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
808
Jinan
2025-01-15
Not yet open
Guangdong Provincial People's Hospital
Early Phase 1
40
Guangzhou
2025-01
Recruiting
Energenx Medical LTD.
Not applicable
126
Shanghai
2024-12-25
Recruiting
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
NCT06714708NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy, Sintilimab
Anhui Provincial Cancer Hospital
Phase 2
86
Hefei
2024-11-20
Not yet open
Sun Yat-sen University
Phase 2
55
Guangzhou
2024-11-02
By invitation
Shanghai Chest Hospital
Observational
500
Shanghai
2024-11-01
Active, closed
Guangdong Provincial People's Hospital
Observational
330
Guangzhou
2024-08-30
Recruiting
Sichuan Cancer Hospital and Research Institute
Phase 2
20
Chengdu
2024-08-01
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
NCT06534762NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
DrugMirabegron
Zhejiang Provincial People's Hospital
Phase 2
260
Hangzhou
2024-07-15
Active, closed
Fudan University
Phase 2
41
Shanghai
2024-07-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Not yet open
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2024-06
Recruiting
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
NCT06431685NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
DrugsSintilimab·Pemetrexed
Sichuan University
Phase 1
10
Chengdu
2024-04-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
51
Tianjin
2024-03-20
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2024-03-01
Not yet open
Sun Yat-sen University
Phase 2
40
Guangzhou
2024-02-01
Recruiting
Zibo Municipal Hospital
Phase 2
20
Zibo
2024-01-13
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
Xueqin Yang
Observational
44
Chongqing
2023-11-13
Recruiting
Study on c-Met Targeted PET/CT Imaging in NSCLC
NCT06911697PET/CT Imaging, NSCLC
Xilin Sun
Not applicable
88
Harbin
2023-10-26
Recruiting
Peking Union Medical College
Not applicable
150
Beijing
2023-10-10
Recruiting
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
110
Shanghai
2023-07-13
Recruiting
Base Therapeutics (Shanghai) Co., Ltd.
Early Phase 1
12
Nanjing
2023-07-01
Active, closed
Biotheus Inc.
Phase 2
64
Guangzhou
2023-06-26
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Active, closed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Active, closed
Allist Pharmaceuticals, Inc.
Phase 2
100
Changchun
2022-09-27
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Jinan
2022-08-25
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
60
Zhengzhou
2022-06-20
Recruiting
TYK Medicines, Inc
Phase 3
680
Changsha, Shanghai
2022-06-08
Not yet open
Liaoning Cancer Hospital & Institute
Phase 2
45
Shenyang
2022-01-01
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
DrugCrizotinib
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
NCT05615142NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy, PD-1 Inhibitor
DrugVenetocalx
Sichuan University
Phase 1
9
Chengdu
2021-12-15
Active, closed
Shanghai Chest Hospital
Phase 2
35
Shanghai
2021-10-27
Active, closed
Allist Pharmaceuticals, Inc.
Phase 1/2
315
Beijing
2021-07-26
Recruiting
Zibo Municipal Hospital
Phase 2
20
Zibo
2021-05-25
Active, closed
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
152
Tianjin
2021-05-07
Active, closed
Akeso
Phase 2
265
Guanzhou
2021-02-01
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512Lung, Lung Cancer, Cancer, NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2019-06-01
Recruiting
Shanghai Chest Hospital
Observational
500
Shanghai
2019-01-01
Recruiting
Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
NCT04522687NSCLC, Esophageal Squamous Cell Carcinoma, Thymic Epithelial Tumor
Shanghai Cancer Hospital, China
Observational
500
Shanghai
2012-01-01
Rows per page Showing 1–84 of 84
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/condition/nsclc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 84 of those studies listing the condition NSCLC.

How many NSCLC trials are recruiting in China?

52 of the 84 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 16 have not yet opened recruitment, 15 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (NSCLC), 84 studies
PhaseStudiesRecruitingShare
Phase 2422450%
Observational11713.1%
Not applicable667.1%
Phase 1647.1%
Phase 1/2637.1%
Phase 3647.1%
Early Phase 1434.8%
Phase 4313.6%

Most active sponsors

Lead sponsors with the most studies (NSCLC)
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital52
Shanghai Chest Hospital42
Allist Pharmaceuticals, Inc.31
Fudan University31
Sichuan University31
Betta Pharmaceuticals Co., Ltd.22
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Guangdong Provincial People's Hospital20
Henan Cancer Hospital21
Jiangsu Cancer Institute & Hospital21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.